PhenixFIN (PFX) Competitors $49.25 -0.12 (-0.24%) Closing price 03:26 PM EasternExtended Trading$49.25 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock PFX vs. HQL, JOF, LEO, MYN, ZTR, KTF, TWN, MIN, MHN, and NCAShould you be buying PhenixFIN stock or one of its competitors? The main competitors of PhenixFIN include abrdn Life Sciences Investors (HQL), Japan Smaller Capitalization Fund (JOF), BNY Mellon Strategic Municipals (LEO), BlackRock MuniYield New York Quality Fund (MYN), Virtus Total Return Fund (ZTR), DWS Municipal Income Trust (KTF), Taiwan Fund (TWN), MFS Intermediate Income Trust (MIN), BlackRock MuniHoldings New York Quality Fund (MHN), and Nuveen California Municipal Va (NCA). These companies are all part of the "financial services" industry. PhenixFIN vs. Its Competitors abrdn Life Sciences Investors Japan Smaller Capitalization Fund BNY Mellon Strategic Municipals BlackRock MuniYield New York Quality Fund Virtus Total Return Fund DWS Municipal Income Trust Taiwan Fund MFS Intermediate Income Trust BlackRock MuniHoldings New York Quality Fund Nuveen California Municipal Va abrdn Life Sciences Investors (NYSE:HQL) and PhenixFIN (NYSE:PFX) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Is HQL or PFX a better dividend stock? abrdn Life Sciences Investors pays an annual dividend of $1.89 per share and has a dividend yield of 13.5%. PhenixFIN pays an annual dividend of $0.48 per share and has a dividend yield of 1.0%. PhenixFIN pays out 15.7% of its earnings in the form of a dividend. Which has more volatility & risk, HQL or PFX? abrdn Life Sciences Investors has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, PhenixFIN has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Do insiders & institutionals have more ownership in HQL or PFX? 32.2% of abrdn Life Sciences Investors shares are held by institutional investors. Comparatively, 43.3% of PhenixFIN shares are held by institutional investors. 10.1% of abrdn Life Sciences Investors shares are held by insiders. Comparatively, 24.4% of PhenixFIN shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer HQL or PFX? In the previous week, PhenixFIN had 4 more articles in the media than abrdn Life Sciences Investors. MarketBeat recorded 9 mentions for PhenixFIN and 5 mentions for abrdn Life Sciences Investors. PhenixFIN's average media sentiment score of 0.96 beat abrdn Life Sciences Investors' score of 0.50 indicating that PhenixFIN is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment abrdn Life Sciences Investors 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PhenixFIN 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HQL or PFX more profitable? PhenixFIN has a net margin of 72.98% compared to abrdn Life Sciences Investors' net margin of 0.00%. PhenixFIN's return on equity of 2.95% beat abrdn Life Sciences Investors' return on equity.Company Net Margins Return on Equity Return on Assets abrdn Life Sciences InvestorsN/A N/A N/A PhenixFIN 72.98%2.95%1.68% Which has stronger valuation and earnings, HQL or PFX? PhenixFIN has higher revenue and earnings than abrdn Life Sciences Investors. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioabrdn Life Sciences InvestorsN/AN/AN/AN/AN/APhenixFIN$15.73M6.27$18.62M$3.0616.09 SummaryPhenixFIN beats abrdn Life Sciences Investors on 8 of the 11 factors compared between the two stocks. Get PhenixFIN News Delivered to You Automatically Sign up to receive the latest news and ratings for PFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PFX vs. The Competition Export to ExcelMetricPhenixFINClosed IndustryFinance SectorNYSE ExchangeMarket Cap$98.70M$69.17M$12.32B$20.92BDividend YieldN/AN/A5.56%3.59%P/E Ratio6.043.2119.5528.16Price / Sales6.273.3525.7756.93Price / Cash20.4180.2518.7717.81Price / Book0.610.352.254.57Net Income$18.62M$119.81M$1.01B$993.62M7 Day Performance-0.46%0.43%1.18%2.33%1 Month Performance-0.40%-2.55%0.82%1.41%1 Year Performance4.71%-41.60%543.75%13.75% PhenixFIN Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PFXPhenixFIN3.7328 of 5 stars$49.25-0.2%N/A+4.7%$98.70M$15.73M6.047HQLabrdn Life Sciences InvestorsN/A$13.32+0.9%N/A-10.8%$384.55MN/A0.00N/ANews CoverageDividend CutShort Interest ↓JOFJapan Smaller Capitalization FundN/A$10.50+0.8%N/A+34.3%$369.28MN/A0.00N/APositive NewsDividend AnnouncementEx-DividendShort Interest ↓LEOBNY Mellon Strategic MunicipalsN/A$5.88-0.6%N/A-7.5%$365.95MN/A0.00147,000News CoveragePositive NewsMYNBlackRock MuniYield New York Quality FundN/A$9.44-0.1%N/A-10.8%$361.61MN/A0.00N/APositive NewsEx-DividendZTRVirtus Total Return FundN/A$6.24+0.1%N/A+9.4%$346.35MN/A0.00N/APositive NewsKTFDWS Municipal Income TrustN/A$8.65-0.2%N/A-11.7%$340.02MN/A0.00N/APositive NewsDividend AnnouncementTWNTaiwan FundN/A$48.64+2.2%N/A+14.0%$315.16MN/A0.00N/AMINMFS Intermediate Income TrustN/A$2.70+0.6%N/A-1.1%$306.12MN/A0.00N/APositive NewsMHNBlackRock MuniHoldings New York Quality FundN/A$9.70-0.1%N/A-10.3%$292.84MN/A0.00N/AEx-DividendNCANuveen California Municipal VaN/A$8.61-0.1%N/A-5.3%$285.08MN/A0.00N/APositive NewsEx-Dividend Related Companies and Tools Related Companies HQL Alternatives JOF Alternatives LEO Alternatives MYN Alternatives ZTR Alternatives KTF Alternatives TWN Alternatives MIN Alternatives MHN Alternatives NCA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PFX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PhenixFIN Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PhenixFIN With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access